Ocugen

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the publication of “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” which appeared in Frontiers in Immunology. BBV152, commercialized …

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology Read More